Mestag Therapeutics announced the appointment of expert advisors Dr. Cassandra Choe-Juliak MD, formerly Chief Medical Officer at Flame Biosciences; Dr. Greg Elson, an expert in end-to-end development of novel antibody-based products with more than 30 years of industry experience; and Samantha Vieira MBA PMP, formerly Chief Operating Officer at Anjarium Biosciences.
Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.
Victrex plc, a pioneer in the development of PEEK biomaterial solutions, have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications.
AlzeCure Pharma AB announced that the company’s presentation at the pain conference held by the Swedish Pain Society is now available in its entirety on the company’s website.
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, announces that Dr. Jeffrey Lawson, currently the Company’s Chief Scientific Officer, will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has unveiled the results of its Hexvix® Phase III clinical trial in China.
New guidance has been issued for clinicians on the determination of brain death, also known as death by neurologic criteria.
Astria Therapeutics, Inc. announced the pricing of an underwritten offering of 8,253,895 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 6,190,418 shares of common stock, and to certain investors in lieu of common stock who so choose, pre-funded warrants to purchase up to an aggregate of 1,571,093 shares
EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement Read More »
Immetas Therapeutics and GC Biopharma announced that they have entered into a research collaboration to discover and develop novel mRNA therapeutics for the treatment of a broad range of autoimmune diseases.
